Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.62 |
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | PGR | P06401 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6921831 | 0.91 | CYP11B2 (0.62) | CYP11B2SLC22A12CYP11B1JAK2JAK3 | |
| SCHEMBL14151820 | 0.83 | CYP11B2 (0.73) | CYP11B2 | |
| SCHEMBL1769941 | 0.79 | CYP11B2 (0.53) | CYP11B2SLC22A12CYP11B1 | |
| SCHEMBL6921215 | 0.77 | CYP11B2 (1.00) | CYP11B2 | |
| SCHEMBL6921318 | 0.76 | CYP11B2 (0.73) | CYP11B2 | |
| SCHEMBL1769883 | 0.71 | PLAU (0.41) | CYP11B2SLC22A12CYP11B1PGRJAK2 | |
| SCHEMBL6920241 | 0.71 | CYP11B2 (0.39) | CYP11B2SLC22A12CYP11B1JAK2JAK3 | |
| SCHEMBL6920044 | 0.70 | CYP11B2 (0.65) | CYP11B2 | |
| SCHEMBL1769875 | 0.66 | CYP11B2 (0.51) | CYP11B2CYP11B1 | |
| SCHEMBL14152211 | 0.65 | CYP11B2 (0.50) | CYP11B2SLC22A12CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP11B2 4/4885SLC22A12 2415/4885CYP11B1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.